INVA

Innoviva's stock price increased by 11.56% between September 29, 2025, and September 28, 2026, and gained 22.4% over the past 12 months. Recent stock events include the announcement of participation in investor conferences on September 2, 2026, and Innoviva Specialty Therapeutics' antimicrobial therapies being designated finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award on August 11, 2026. The company reported its Second Quarter 2026 financial results on August 5, 2026. On June 16, 2026, Innoviva Specialty Therapeutics announced a distribution and licensing agreement with Dr. Reddy's for XACDURO in select international markets. Innoviva reported its First Quarter 2026 financial results on May 6, 2026, highlighting 37% year-over-year net product sales growth for Innoviva Specialty Therapeutics and continued its $125 million share repurchase program. On February 25, 2026, the company reported Fourth Quarter and Full Year 2025 financial results, noting 15% revenue growth and 47% year-over-year U.S. sales growth for Innoviva Specialty Therapeutics, along with the successful mid-2025 launch of ZEVTERA in the U.S. and the FDA approval of NUZOLVENCE in December 2025.